跳至主要内容
临床试验/NCT02484872
NCT02484872Unknown不适用

L'Inflammation A-t-elle Une Implication Significative Dans l'évolution du Cancer Bronchique?

European Lung Cancer Working Party1 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2015年5月最近更新:
适应症

试验速览

阶段
不适用
入组人数
400
试验地点
1
主要终点
Survival

研究概览

简要总结

Systemic inflammation is a potential prognostic factor in cancer. Inflammation scores as the Glasgow score have been tested in cancer and specifically in lung cancer patients. The aim of the study is to look at the prognostic and predictive value of inflammation during cancer evolution, on the risk of complications leading to ICU admission and the risk of death.

详细描述

Patients with newly diagnosed lung cancer will be eligible. All patients will have a blood sampling allowing testing inflammation and cytokine analyses at diagnosis, during work-up and in case of complication.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Lung neoplasms irrespective of stage, histology

排除标准

  • Previously treated lung neoplasms
  • A history of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix or cured malignant tumour (more than 5 year disease-free interval)

结局指标

主要结局

Survival

时间窗: Measured from diagnosis until death or last date known to be alive, or at least 48 months

次要结局

  • Complications leading to emergency/ICU(From inclusion until death, or a least 48 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验